Pfizer Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: PFE Category:


Pfizer has been among the list of favorites for pharma blue-chip investors as well as dividend-focused investors for many years and the COVID-19 vaccine-related upside has only augmented the demand. With the burden of the laggard Upjohn business off its shoulders, the company is poised for strong growth in 2021 not only through its first mover’s advantage on the COVID-19 vaccine front but also through a promising pipeline of launches in the year.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!